Immune Checkpoint Inhibitors to Treat Malignant Lymphomas

Journal of Immunology Research
Magdalena Witkowska, Piotr Smolewski

Abstract

Genetic and/or epigenetic changes provide antigen-derived diversity in neoplastic cells. Beside, these cells do not initiate immune response of host organisms. A variety of factors are responsible for the resistant to treatment, including individual variations in patients and somatic cell genetic differences in tumors, even those from the same tissue of origin. Immune system is controlled by several controlling mechanisms. Recently, a significant progress in hematologic treatment has been made; however, majority of diseases still remain incurable. Immunotherapy with checkpoint inhibitors has emerged as promising modality of antitumor treatment, showing marked response to several antigens, including cytotoxic T lymphocyte-associate protein-4 (CTLA-4) or programmed cell death 1 receptor (PD-1). In this review, we demonstrate actual knowledge on immune checkpoint function and its impact on development of new modality of antineoplastic treatment, using, for example, anti-CTLA-4 or PD-1/PD1 ligand (PD-L1) monoclonal antibodies in malignant lymphomas.

References

May 1, 1990·The Journal of Experimental Medicine·F TriebelT Hercend
Nov 8, 2002·The Journal of Immunology : Official Journal of the American Association of Immunologists·Creg J WorkmanDario A A Vignali
Aug 9, 2003·Critical Reviews in Immunology·Brendan O'Sullivan, Ranjeny Thomas
Mar 3, 2004·European Journal of Immunology·Simona RonchettiCarlo Riccardi
Jun 8, 2004·Immunologic Research·Robert S MittlerL Becker Hewes
Oct 16, 2004·Immunity·Ching-Tai HuangDario A A Vignali
Jan 19, 2006·The Journal of Investigative Dermatology·Henry K WongHenry W Lim
Jul 11, 2006·Annual Review of Genomics and Human Genetics·Arman A BashirovaMary Carrington
May 4, 2007·The Journal of Clinical Investigation·Jeremy B Swann, Mark J Smyth
Oct 13, 2007·The Journal of Clinical Investigation·Joseph F GrossoCharles G Drake
Jan 8, 2008·The Journal of Immunology : Official Journal of the American Association of Immunologists·Yvonne BurmeisterAndreas Hutloff
Mar 22, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B SirohiA Horwich
May 17, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Raanan BergerArnon Nagler
Jul 3, 2008·The American Journal of Surgical Pathology·Syong H Nam-ChaMiguel A Piris
Jul 22, 2008·The Journal of Immunology : Official Journal of the American Association of Immunologists·Petra BochtlerJörg Reimann
Jan 1, 2009·Arthritis and Rheumatism·Paula KolarMonika C Brunner-Weinzierl
Feb 20, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Joaquim CarrerasElias Campo
May 12, 2009·Immunological Reviews·Michael CroftPejman Soroosh
Jun 23, 2009·European Journal of Immunology·Judith LeitnerPeter Steinberger
Aug 14, 2009·European Journal of Immunology·William D HastingsVijay K Kuchroo
Oct 8, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Stephen M AnsellJohn M Timmerman
Apr 14, 2010·Proceedings of the National Academy of Sciences of the United States of America·Junko MatsuzakiKunle Odunsi
Sep 8, 2010·The Journal of Experimental Medicine·Kaori SakuishiAna C Anderson
May 5, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·David J AndorskyJohn M Timmerman
Jan 25, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Michael R GreenMargaret A Shipp
Feb 22, 2012·Nature Reviews. Immunology·Onur Boyman, Jonathan Sprent
Mar 20, 2012·The Journal of Clinical Investigation·Zhi-Zhang YangStephen M Ansell
Mar 23, 2012·Nature Reviews. Cancer·Drew M Pardoll
Apr 17, 2012·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Hang LiWeiping Zou
Sep 7, 2012·The Journal of Investigative Dermatology·Heather M GibsonHenry K Wong
Jan 22, 2013·CA: a Cancer Journal for Clinicians·Rebecca SiegelAhmedin Jemal
May 16, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Benjamin J ChenScott J Rodig
Dec 10, 2013·Advances in Anatomic Pathology·Rebecca L KingAdam Bagg
Apr 3, 2014·Cancer Research·J Louise LinesRandolph Noelle
Apr 9, 2014·Cancer Immunology, Immunotherapy : CII·George C PrendergastAlexander J Muller

❮ Previous
Next ❯

Citations

Nov 2, 2018·Genes, Chromosomes & Cancer·Jean-Jacques MichailleEsmerina Tili
Nov 7, 2019·Journal of Cellular Biochemistry·Tiesuo ZhaoZhiwei Feng
Nov 12, 2019·Cell Biochemistry and Function·Yizhen LiuXiaojian Liu
Jun 18, 2020·Cancers·Gaël Roué, Brigitte Sola
Jun 20, 2019·Frontiers in Oncology·Stefania CrisciAntonio Pinto
Feb 25, 2021·BioMed Research International·Carlos Barrera-AvalosClaudio Acuña-Castillo
Feb 26, 2021·Seminars in Cancer Biology·Yin WuCharles Swanton
Apr 18, 2021·Clinical and Experimental Immunology·Gaetane NocturneXavier Mariette
Mar 3, 2021·International Braz J Urol : Official Journal of the Brazilian Society of Urology·Ercília Rita MondlaneFernando Mendes

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT02572167
NCT01896999
NCT02940301

Related Concepts

Related Feeds

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Antigenic Modulation

Antigenic modulation occurs when an antibody cross-links antigens on a cell surface, causing the antigens to become internalized. This can lead to therapeutic failure of monoclonal antibodies as the expression of the antigen becomes decreased on target cells. Find the latest research on antigenic modulation here.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Related Papers

Archives of Pharmacal Research
Junsik ParkEui-Cheol Shin
Annals of Translational Medicine
Cristina TeixidóRafael Rosell
© 2022 Meta ULC. All rights reserved